Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 199

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4A
Chunk 199
---
 than 0.65% of the net sales of our products sold by our licensees
in a given year) on any royalties or revenues received by us from our licensees.

Under an Operations Partner
Agreement between us and services provider HekaBio K. K. of May 21, 2019, we make certain payments to HekaBio K. K. in exchange for consulting
and administrative services in Japan, as well as payments upon the achievement of certain clinical and regulatory milestones. In addition,
if HekaBio K. K. successfully assists us in obtaining regulatory marketing approval of our products in Japan, then we are to grant to HekaBio
K. K. options to acquire 271,588 of our Ordinary shares at a price of $4.42 each, and to pay HekaBio K. K. a royalty of 3.5% of the reimbursement
price (as defined in the agreement) of such products in Japan and 10% of revenues received by us from distribution receipts (as defined
in the agreement) for such products in Japan.

On November 18, 2018 and July
29, 2019, we entered into research and license agreements with BGN Technologies, the technology transfer company of Ben Gurion University
(“ BGN”), further amended on May 12, 2021, wherein we will wholly own any intellectual property that is developed jointly by
Ben Gurion University and others (including us), and BGN will receive 0.75% royalties on all sales of our alpha radiation products, net
of certain deductions and irrespective of the intellectual property underlying such sales, or 1.5% royalties on sales of products that
contain intellectual property owned by Ben Gurion University, net of certain deductions. BGN will receive 4% of license revenues (as defined
in the agreements) that relate to jointly developed intellectual property, and 8% of license revenues that relate to intellectual property
developed solely by Ben Gurion University. The parties also agreed that we will continue to conduct research at Ben Gurion University
for as long as the researchers wish to, and the parties have agreed on a research budget in good faith.

On December 1, 2020, we entered
into a clinical trial agreement with Cambridge University Hospitals NHS Trust, wherein Cambridge will receive 5% of any marginal increase
in our net sales (all as defined in the agreement) generated on account of any patent or patent claim granted from the